|
"Target Specific and Drug Loaded Iron Oxide Nanoparticles for Cancer Imaging and
|
N44CO120029-000
|
$1,200,000
|
WANG, ANDREW
|
OCEAN NANO TECH LLC
|
|
1H NMR STUDIES OF NON-HODGKINS LYMPHOMA
|
5R01CA101700-08
|
$358,748
|
GLICKSON, JERRY
|
UNIVERSITY OF PENNSYLVANIA
|
|
4'-Substituted nucleoside analogs as anticancer drugs
|
5R01CA124952-05
|
$441,240
|
SECRIST, JOHN
|
SOUTHERN RESEARCH INSTITUTE
|
|
A Decision Aid with HRQL Assessment to Reduce Costs in the Treatment of NSCLC
|
1R01CA157409-01A1
|
$660,655
|
HOLLEN, PATRICIA
|
UNIVERSITY OF VIRGINIA
|
|
A Model for Preclinical Biomarker Discovery in Pancreatic Ductal Adenocarcinoma
|
5K08CA137153-03
|
$163,080
|
Collisson, Eric
|
UNIVERSITY OF CALIFORNIA-SAN FRANCISCO
|
|
A New Web 2.0 Platform for Analyzing Genomics Data with Application to the S
|
5R42CA139639-03
|
$397,700
|
Johnson, Wayne
|
MYATT AND JOHNSON, INC.
|
|
A novel combination therapy for the treatment of Pancreatic adenocarcinoma
|
5R03CA149857-02
|
$74,250
|
HOLLINGSWORTH, MICHAEL
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
A novel diagnostic test for Irinotecan and Topotecan sensitivity
|
1R41CA162548-01
|
$205,818
|
GJERSET, RUTH
|
RG BIOPHARMA, LLC
|
|
A Phase I trial combining fenretinide and safingol to target overproduction of di
|
5R21CA161889-02
|
$311,717
|
REYNOLDS, CHARLES
|
TEXAS TECH UNIVERSITY HEALTH SCIS CENTER
|
|
A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL
|
5R21CA161688-02
|
$321,931
|
Burke, Michael
|
UNIVERSITY OF MINNESOTA
|
|
A Role of Bit1 in the Apoptosis Resistance, Anoikis Insensitvity, and Chemoresist
|
1R15CA158677-01A1
|
$362,890
|
Biliran, Hector
|
XAVIER UNIVERSITY OF LOUISIANA
|
|
A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors
|
1R41CA174031-01
|
$266,641
|
Jones, Barry
|
ARISAPH PHARMACEUTICALS, INC.
|
|
A Suite of Tumor Targeting Peptides for Personalized Therapy of Lung Cancer
|
1R01CA164447-01A1
|
$313,615
|
BROWN, KATHLYNN
|
UNIV OF TX SW MED CTR-DALLAS
|
|
A Topical Host Defense Peptide Mimetic for Oral Mucositis
|
1R43CA171376-01
|
$161,376
|
SCOTT, RICHARD
|
POLYMEDIX, INC,
|
|
A Translational Model of Evolution of Myeloma Adhesion-Mediated Drug Resistance
|
1R21CA164322-01
|
$235,401
|
Silva, Ariosto
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
A Universal Approach to Personalized Adoptive T cell Therapy of Cancer
|
1R01CA168900-01
|
$332,000
|
Powell, Daniel
|
UNIVERSITY OF PENNSYLVANIA
|
|
ABC: Antidepressants and Breast Cancer Pharmacoepidemiology
|
5R01CA136743-03
|
$490,004
|
HAQUE, REINA
|
KAISER FOUNDATION RESEARCH INSTITUTE
|
|
Aberrant activation of HGF/MET signaling as a therapeutic target in AML
|
5K08CA160660-02
|
$156,330
|
Kentsis, Alex
|
DANA-FARBER CANCER INSTITUTE
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-36
|
$7,725,062
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
ACOSOG Community Clinical Oncology Program (CCOP) Research Base
|
5U10CA149950-02
|
$1,474,780
|
Sloan, Jeff
|
MAYO CLINIC
|
|
ACOSOG Competing Renewal
|
7U10CA076001-16
|
$2,940,780
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Action of RB Pathway in Breast Cancer Therapy
|
5R01CA129134-03
|
$311,976
|
KNUDSEN, ERIK
|
THOMAS JEFFERSON UNIVERSITY
|
|
Adaptable Polymer Micelles for Tumor Targeting
|
5R01CA129287-03
|
$299,829
|
PARK, KINAM
|
PURDUE UNIVERSITY WEST LAFAYETTE
|
|
Adoption and Retooling of GEM model for Pancreatic Cancer
|
ZIABC011463
|
$148,216
|
Van Dyke, Terry
|
CCR (NCI)
|
|
Adoptive Immunotherapy for GBM During Hematopoietic Recovery from Temozolomide
|
5R01CA134844-04
|
$312,186
|
MITCHELL, DUANE
|
DUKE UNIVERSITY
|
|
Adult Brain Tumor Consortium (ABTC)
|
5U01CA137443-04
|
$1,818,177
|
GROSSMAN, STUART
|
JOHNS HOPKINS UNIVERSITY
|
|
Aerobic Training During or After Adjuvant Therapy: A Randomized Trial
|
1R01CA164751-01A1
|
$627,768
|
JONES, LEE
|
DUKE UNIVERSITY
|
|
AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia
|
5R01CA139032-04
|
$322,040
|
Muschen, Markus
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
AIDS and Cancer Specimen Resource Central Office and Data Coordinating Center
|
5U01CA096230-10
|
$832,033
|
MCGRATH, MICHAEL
|
UNIVERSITY OF CALIFORNIA-SAN FRANCISCO
|
|
AIDS Malignancy Clinical Trials Consortium (AMC)
|
3U01CA121947-05S1
|
$450,000
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA AT LOS ANGELES
|
|
AIDS Malignancy Clinical Trials Consortium (AMC)
|
5U01CA121947-06
|
$6,010,333
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA AT LOS ANGELES
|
|
Akt Inhibitor MK-2206 for Breast Cancers with a PIK3CA Mutation and/or PTEN loss
|
5R21CA159270-02
|
$262,015
|
MERIC-BERNSTAM, FUNDA
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
ALL therapy and developing brains: MRI measures, genetic factors and cognition
|
5R01CA090246-07
|
$380,224
|
REDDICK, WILBURN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
An agent for the treatment of lung cancer
|
1R43CA165448-01
|
$299,999
|
Komninou, Despina
|
MEDICON, INC.
|
|
Analog Studies of 4-HPR and its Glucuronide
|
5R01CA049837-18
|
$331,716
|
CURLEY, ROBERT
|
OHIO STATE UNIVERSITY
|
|
ANALYSIS OF ANTI-CANCER CHEMICALS AND PHARMACEUTICAL FORMULATIONS
|
N02CM722001-008
|
$9,800
|
WHITE, JONATHAN
|
MIDWEST RESEARCH INSTITUTE
|
|
Analysis of Anti-Cancer Chemicals and Pharmaceutical Formulations
|
N02CM120027-000
|
$50,000
|
HINES, JOHN
|
RESEARCH TRIANGLE INSTITUTE
|
|
ANALYSIS OF ANTI-CANCER CHEMICALS AND PHARMACEUTICAL FORMULATIONS
|
N02CM722003-009
|
$80,400
|
WANG, JENNIE
|
SRI INTERNATIONAL
|
|
Analysis of Anti-Cancer Chemiclas & Pharmaceutical Formulations
|
N02CM120026-000
|
$74,000
|
WHITE, JONATHAN
|
MIDWEST RESEARCH INSTITUTE
|
|
Analysis of Redox Modulated Signaling Networks in Response to Ionizing Radiation
|
5R01CA136810-04
|
$295,025
|
Furdui, Cristina
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
Analysis of the leukemic stem cell niche in chronic myeloid leukemia
|
5K08CA138916-03
|
$162,568
|
Krause, Daniela
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Anthrax Toxin Receptor as a marker and target of breast cancer stem cells
|
5R21CA152536-02
|
$167,475
|
NAKSHATRI, HARIKRISHNA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Anti-CTLA-4 enhances the effects of imatinib in gastrointestinal stromal tumor
|
5F32CA162721-02
|
$55,670
|
Kim, Teresa
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Anti-topoisomerase drug action in yeast
|
5R01CA052814-19
|
$282,872
|
NITISS, JOHN
|
UNIVERSITY OF ILLINOIS
|
|
Anti-Tumor Mechanisms and Therapeutic Effects of Vitamin D
|
5R01CA067267-18
|
$430,613
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Antibody directed delivery of short interfering RNA for the treatment of ovarian
|
1K08CA163603-01A1
|
$170,631
|
PALANCA-WESSELS, MARIA
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Antibody-interferon fusion proteins for treatment of B-cell malignancies
|
5R01CA162964-02
|
$319,550
|
MORRISON, SHERIE
|
UNIVERSITY OF CALIFORNIA AT LOS ANGELES
|
|
Anticancer Agents: Structure and Synthesis
|
5R01CA019033-36
|
$245,060
|
Smith, Amos
|
UNIVERSITY OF PENNSYLVANIA
|
|
ANTICANCER DRUG DISCOVERY THAT TARGETS TUMOR HYPOXIA
|
5R01CA098787-08
|
$262,130
|
NAGLE, DALE
|
UNIVERSITY OF MISSISSIPPI
|
|
Anticancer Drug Pharmacology in Very Young Children
|
1R01CA154619-01A1
|
$433,475
|
STEWART, CLINTON
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|